Sustained and controlled release preparation for pharmaceutical composition for curing hypertension

A technology for controlled release preparations and high blood pressure, which is applied in the field of angiotensin II receptor blockers and sustained and controlled release preparations for the treatment of high blood pressure. The protection of structure and function, the reduction of drug side effects, and the effect of overcoming drug defects

Active Publication Date: 2009-10-28
LUNAN PHARMA GROUP CORPORATION
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Chinese patents CN1312715 and CN1733307 disclose a kind of pharmaceutical composition for the treatment or prevention of diabetes, hypertension accompanied by diabetes, and diabetic nephropathy, comprising valsartan and calcium channel blockers, but this invention only mentions the use of prior art to make this Pharmaceutical compositions made into tablets, capsules, suppositories
[0005] Chinese patent CN1883478 discloses a pharmaceutical composition for treating hypertensive cardiovascular disease, comprising levamlodipine and losartan, irbesartan, valsartan, eprosartan, candesartan or tasosartan Tan, and discloses that the pharmaceutical composition can be made into tablets, granules, capsules, injections, and sustained-release formulations. However, the sustained-release formulations are only briefly mentioned, and no specific technical solutions are given.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained and controlled release preparation for pharmaceutical composition for curing hypertension
  • Sustained and controlled release preparation for pharmaceutical composition for curing hypertension
  • Sustained and controlled release preparation for pharmaceutical composition for curing hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] The preparation of embodiment 1 sustained release tablet

[0040] Sustained release part

[0041] Levoamlodipine Besylate 5g

[0042] Hydroxypropyl Methyl Cellulose 8g

[0043] Lactose 12g

[0044] 80% ethanol solution appropriate amount

[0045] common part

[0046] Candesartan cilexetil 2.5g

[0047] Microcrystalline Cellulose 15g

[0048] Dextrin 3g

[0049] 70% ethanol solution of 3% PVPk30 appropriate amount

[0050] Magnesium stearate 0.6g

[0051] Preparation Process:

[0052] First pass levamlodipine besylate and candesartan cilexetil through a 100-mesh sieve; hydroxypropyl methylcellulose, microcrystalline cellulose, lactose, and dextrin pass through an 80-mesh sieve.

[0053] Weigh levamlodipine besylate, hydroxypropyl methylcellulose, and lactose according to the prescription amount, mix them evenly, add 80% ethanol solution to make soft materials, pass through a 18-mesh sieve to granulate, and the wet granules are between 50 and 60 Dry at ℃, sieve...

Embodiment 2

[0055] The preparation of embodiment 2 sustained-release tablets

[0056] Sustained release part

[0057] Levoamlodipine Besylate 2.5g

[0058] Hydroxypropyl Methyl Cellulose 8g

[0059] Lactose 12g

[0060] 80% ethanol solution appropriate amount

[0061] common part

[0062] Candesartan cilexetil 4g

[0063] Microcrystalline Cellulose 15g

[0064] Starch 3g

[0065] 70% ethanol solution of 3% PVPk30 appropriate amount

[0066] Magnesium stearate 0.5g

[0067] Preparation Process:

[0068] First pass levamlodipine besylate and candesartan cilexetil through a 100-mesh sieve; hydroxypropyl methylcellulose, microcrystalline cellulose, lactose, and starch pass through an 80-mesh sieve.

[0069] Weigh levamlodipine besylate, hydroxypropyl methylcellulose, and lactose according to the prescription amount, mix them evenly, add 80% ethanol solution to make soft materials, pass through a 18-mesh sieve to granulate, and the wet granules are between 50 and 60 Dry at ℃, sieve th...

Embodiment 3

[0071] The preparation of embodiment 3 sustained-release tablets

[0072] Sustained release part

[0073] Levoamlodipine Besylate 5g

[0074] Hydroxypropyl Methyl Cellulose 750g

[0075] Lactose 120g

[0076] 80% ethanol solution appropriate amount

[0077] common part

[0078] Eprosartan Mesylate 600g

[0079] Microcrystalline Cellulose 450g

[0080] Starch 300g

[0081] 70% ethanol solution of 3% PVPk30 appropriate amount

[0082] Magnesium Stearate 5g

[0083] Preparation Process:

[0084] First pass levamlodipine besylate and eprosartan mesylate through a 100-mesh sieve; hydroxypropyl methylcellulose, microcrystalline cellulose, lactose, and starch pass through an 80-mesh sieve.

[0085] Weigh levamlodipine besylate, hydroxypropylmethyl cellulose and lactose according to the prescription amount, mix the main drug levamlodipine besylate with the auxiliary materials by equal increment method, add 80% ethanol solution to make soft The material is granulated through...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a sustained and controlled release preparation for a pharmaceutical composition for curing hypertension. The sustained and controlled release preparation composition includes a specific proportion of levamlodipine and angiotensin II receptor blocking pharmacon, wherein the levamlodipine is taken as the sustained and controlled release part and the angiotensin II receptor blocking pharmacon is taken as the common release part. The provided sustained and controlled release preparation enhances the therapeutic effect and reduces the treatment risk of the patients.

Description

Technical field: [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a sustained and controlled release preparation for treating hypertension containing two active ingredients of medicines, one of which is levamlodipine, and the other is an angiotensin II receptor blocker. Background technique [0002] Hypertension is the most common cardiovascular disease and has become a major public health problem worldwide. According to statistics from the national health department, by the end of 2006, the number of hypertensive patients in my country had reached 160 million, and more than 3 million new patients were added every year. [0003] Hypertension is a syndrome with very complicated etiology and pathogenesis. Once diagnosed, it requires life-long medication. At present, domestic and foreign medical circles generally tend to use two antihypertensive drugs with different mechanisms of action in combination. According to the sixth report of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K9/22A61K9/52A61K31/4422A61K31/519A61P9/12A61K31/4184A61K31/4178A61K31/417A61K31/41
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap